Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isocitric Acid SCHEMBL3179346 | 1.00 | CA4 (0.35) | CA4THRBMEN1KMT2AALDH1A1 | |
| Isocitric Acid SCHEMBL31316947 | 0.98 | CA4 (0.34) | CA4THRBMEN1KMT2AALDH1A1 | |
| SCHEMBL29349496 | 0.82 | THRB (0.32) | CA4THRBMEN1KMT2A | |
| Cadaverine Tartrate SCHEMBL30432913 | 0.82 | THRB (0.46) | THRBMEN1KMT2AANPEPERAP2 | |
| Isocitric Acid SCHEMBL2396430 | 0.78 | CA4 (0.50) | CA4CA2 | |
| Isocitric Acid SCHEMBL2581302 | 0.78 | CA4 (0.50) | CA4CA2 | |
| Isocitric Acid SCHEMBL19138174 | 0.78 | CA4 (0.50) | CA4CA2 | |
| Isocitric Acid SCHEMBL6739630 | 0.78 | CA4 (0.50) | CA4CA2 | |
| Isocitric Acid SCHEMBL2580919 | 0.78 | CA4 (0.50) | CA4CA2 | |
| Isocitric Acid SCHEMBL11648770 | 0.78 | CA4 (0.50) | CA4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193434-A1 | Anti-tumor composition | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | claimed |
| US-20020193362-A1 | Anti-tumor composition | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | claimed |
| CN-116903748-A | anti-AXL antagonistic antibodies | 卑尔根技术锻造股份公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-109311997-B | anti-AXL antagonistic antibodies | 卑尔根技术锻造股份公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116410318-A | anti-AXL antagonistic antibodies | 卑尔根技术锻造股份公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-107207472-B | Inhibitors of AKT kinase | 卑尔根生物股份公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-111246883-A | Treatment of triple negative breast cancer or colorectal cancer with anti-PD-L1 antibody and oncolytic virus with liver metastasis | 美国安进公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-1813613-B1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-12-19 | — | — | EP | disclosed |
| EP-2114942-B1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | MSD KK (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-8030327-B2 | 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle | MDS K.K. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1068870-B1 | ANTITUMOR AGENTS | AJINOMOTO KK (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20050281892-A1 | Highly efficacious and highly safe composition of a Stilbene derivative and a platinum coordination compound cis-diaminedichloroplatinum (II) | AJINOMOTO CO., INC. (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20020193434-A1 | Anti-tumor composition | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | disclosed |
| US-20020193362-A1 | Anti-tumor composition | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1068870-A1 | ANTITUMOR AGENTS | Ajinomoto Co., Inc. (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193434-A1 | Anti-tumor composition | TP53, VHL, MKI67 | CA4 162/4885THRB 2902/4885MEN1 908/4885 |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | CA4 2007/4885THRB 3159/4885MEN1 885/4885 |
| US-20050281892-A1 | Highly efficacious and highly safe composition of a Stilbene derivative and a platinum coordination compound cis-diaminedichloroplatinum (II) | MSH2, TOP2B, TP53 | CA4 1079/4885THRB 3940/4885MEN1 212/4885 |
| US-20020193362-A1 | Anti-tumor composition | TP53, VHL, MKI67 | CA4 162/4885THRB 2902/4885MEN1 908/4885 |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | CA4 1164/4885THRB 2803/4885MEN1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.